Additional Paid-In Capital
Edwards Lifesciences Additional Paid-In Capital increased by 0.5% to $2.78B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.8%, from $2.65B to $2.78B. Over 5 years (FY 2020 to FY 2025), Additional Paid-In Capital shows an upward trend with a 14.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
A consistent increase is common for growth companies that frequently issue stock-based compensation or raise capital through equity markets.
Detailed definition
This represents the excess amount paid by investors for common shares above their stated par value. It is a critical com...
Peer comparison
This is a standard equity account for all publicly traded corporations, representing the cumulative historical premium paid by investors.
equity_additional_paid_in_capital_common_stockHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.58B | $1.64B | $1.70B | $1.77B | $1.85B | $1.91B | $1.97B | $2.05B | $2.15B | $2.21B | $2.27B | $2.38B | $2.48B | $2.45B | $2.61B | $2.65B | $2.75B | $2.70B | $2.77B | $2.78B |
| QoQ Change | — | +4.1% | +3.5% | +4.1% | +4.7% | +3.3% | +2.9% | +4.1% | +4.7% | +3.1% | +2.9% | +4.6% | +4.1% | -1.0% | +6.6% | +1.5% | +3.6% | -1.9% | +2.6% | +0.5% |
| YoY Change | — | — | — | — | +17.3% | +16.5% | +15.8% | +15.8% | +15.8% | +15.5% | +15.5% | +16.1% | +15.4% | +10.9% | +14.9% | +11.5% | +11.1% | +10.0% | +5.9% | +4.8% |
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's additional paid-in capital?
- Edwards Lifesciences (EW) reported additional paid-in capital of $2.78B in Q1 2026.
- How has Edwards Lifesciences's additional paid-in capital changed year-over-year?
- Edwards Lifesciences's additional paid-in capital increased by 4.8% year-over-year, from $2.65B to $2.78B.
- What is the long-term trend for Edwards Lifesciences's additional paid-in capital?
- Over 5 years (2020 to 2025), Edwards Lifesciences's additional paid-in capital has grown at a 14.0% compound annual growth rate (CAGR), from $1.44B to $2.77B.
- What does additional paid-in capital mean?
- The total amount of capital received from shareholders in excess of the nominal par value of the stock.